{
  "docId": "019de077-2e43-774b-aad6-58a03a29d59d",
  "docSlug": "207557819f8810b573d3e2a3179a9bac",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 55 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 34,
  "pageCount": 55,
  "prevPage": 33,
  "nextPage": 35,
  "slideType": "problem_statement",
  "function": "diagnose_problem",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "The slide uses a market segmentation approach to map clinical trials (NIAGARA, POTOMAC, VOLGA, NILE) to patient populations (NMIBC, MIBC, 1L mUC).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-2e43-774b-aad6-58a03a29d59d/34",
  "deckHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d",
  "deckJsonHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d.json",
  "deckAnchorHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d#slide-34",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.09,
        "x": 0.895,
        "y": 0.015
      },
      "kind": "callout",
      "text": "$1bn+*",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a585e4e6-d01e-48b1-b972-d6e3c2e66f49",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.35,
        "x": 0.04,
        "y": 0.45
      },
      "kind": "diagram",
      "text": "Current SoC: Radical cystectomy -> Neoadj. CTx cisplatin-based -> High risk pts: adjuvant IO",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8a0b7cb9-0192-4905-a0e9-98bab679a3db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.04,
        "y": 0.65
      },
      "kind": "list",
      "text": "~5-8% survival benefit with cisplatin-based neoadjuvant CTx vs no neoadjuvant CTx; ~50% patients are cisplatin-eligible; ~50% of patients recur within 5 years of radical cystectomy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b43e3d8-d7ba-4b4b-ae89-67d5cf61aafe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.35,
        "x": 0.04,
        "y": 0.35
      },
      "kind": "metric",
      "text": "~120k MIBC patients across G8",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6026f649-f307-4012-9c63-c0460070789b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.04,
        "y": 0.21
      },
      "kind": "paragraph",
      "text": "NIAGARA addresses significant need in MIBC",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e541f3a1-e0be-40d9-9026-8bc85166b544",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.98,
        "x": 0.01,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "*Non-risk adjusted peak year revenue opportunity for Imfinzi bladder programme. For cisplatin ineligible patients, some guidelines recommend gemcitabine ± paclitaxel (NCCN bladder cancer guidelines V1 2022).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b99975f-48e5-4f9c-bb87-05e8af812215",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.58,
        "x": 0.39,
        "y": 0.23
      },
      "kind": "table",
      "text": "Market segments (NMIBC, MIBC, 1L mUC) with associated trials (POTOMAC, NIAGARA, VOLGA, NILE) and 5-year OS metrics.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b8a999cb-c3d7-4d28-baa5-75d95e484942",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.75,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "NIAGARA establishes AstraZeneca as a key player in bladder cancer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a7b8de36-4a3b-471d-8ae3-397884b4d72c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "e46de2cd-1ffc-4b3e-adf0-909e7b54e9de",
      "evidence": "The slide presents a problem statement and market opportunity.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "market-segmentation",
      "slug": null,
      "matchId": "1dcc85c5-41e1-424f-b735-643ba03fbed1",
      "evidence": "Segmentation of bladder cancer patients into NMIBC, MIBC, and 1L mUC categories.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 35,
      "from": 22,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "e1d82b9f-ab34-4351-be54-5e9df327f1c4",
      "evidence": "The document highlights the high unmet need and presents NIAGARA as a solution.",
      "position": 0,
      "objective": "What is the cost of not addressing the unmet need in muscle-invasive bladder cancer?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}